MedTrace Logo

DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema

NCT06004986 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 216

Last updated 2025-10-08

No results posted yet for this study

Summary

The goal of this randomized controlled trial is to study the (cost)effectiveness of extending the intervals between dupilumab doses in patients with well-controlled atopic eczema, while considering physician- and patient-reported disease severity, quality of life, and dupilumab serum trough levels. Patients will be divided randomly into three groups, receiving dupilumab 300 mg every 2 weeks, every 3 weeks, or every 4 weeks. Researchers will then compare the outcomes among these three groups.

Conditions

Interventions

DRUG

Dupilumab

Administering Dupilumab 300 mg at different dosing intervals.

Sponsors & Collaborators

  • Erasmus Medical Center

    collaborator OTHER

  • Prothya Biosolutions

    collaborator INDUSTRY

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    lead OTHER

Principal Investigators

  • Louise AA Gerbens, MD PhD · Amsterdam University Medical Centers

  • Phyllis I Spuls, MD PhD · Amsterdam University Medical Centers

  • DirkJan Hijnen, MD PhD · Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-14
Primary Completion
2025-10-01
Completion
2025-12-31
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06004986 on ClinicalTrials.gov